Advanced search
Publication Cover
Patient Preference and Adherence Volume 15, 2021 - Issue
Submit an article Journal homepage
129
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Retrospective Analysis of the Effects of Non-Compliance with Denosumab on Changes in Bone Mineral Density During the COVID-19 Pandemic

Chun-Feng Huang1 Department of Family Medicine, National Yang Ming Chiao Tung University Hospital, Yilan, Taiwan (Republic of China);2 Department of Biomedical Sciences, Chang Gung University, Taoyuan, Taiwan (Republic of China)ORCID Iconhttps://orcid.org/0000-0002-6265-5155
ORCID Icon,
Ming-Shi Shiao2 Department of Biomedical Sciences, Chang Gung University, Taoyuan, Taiwan (Republic of China)
&
Tso-Yen Mao3 Department of Leisure Services Management, Chaoyang University of Technology, Taichung, Taiwan (Republic of China)Correspondence[email protected]
Pages 1579-1584 | Published online: 15 Jul 2021

References

  • Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 2006;194(2 Suppl):S3–S11. doi:10.1016/j.ajog.2005.08.047
  • Jackson RD, Donepudi S, Mysiw WJ. Epidemiology of fracture risk in the women’s health initiative. Curr Osteoporos Rep. 2008;6(4):155–161. doi:10.1007/s11914-008-0027-3
  • Jackson RD, Mysiw WJ. Insights into the epidemiology of postmenopausal osteoporosis: the women’s health initiative. Semin Reprod Med. 2014;32(6):454–462. doi:10.1055/s-0034-1384629
  • Aspray TJ, Hill TR. Osteoporosis and the ageing skeleton. Subcell Biochem. 2019;91:453–476. doi:10.1007/978-981-13-3681-2_16
  • Kaunitz AM, McClung MR, Feldman RG, Wysocki S. Postmenopausal osteoporosis: fracture risk and prevention. J Fam Pract. 2009;58(11Suppl Postmenopausal):S1–S6.
  • Bijelic R, Milicevic S, Balaban J. Risk factors for osteoporosis in postmenopausal women. Med Arch. 2017;71(1):25–28. doi:10.5455/medarh.2017.71.25-28
  • Black DM, Rosen CJ. Postmenopausal Osteoporosis. N Engl J Med. 2016;374(3):254–262. doi:10.1056/NEJMcp1513724
  • Fink HA, MacDonald R, Forte ML, et al. Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review. Ann Intern Med. 2019;171(1):37–50. doi:10.7326/M19-0533
  • Zhou J, Ma X, Wang T, Zhai S. Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses. Osteoporos Int. 2016;27(11):3289–3300. doi:10.1007/s00198-016-3654-z
  • Yu EW, Tsourdi E, Clarke BL, Bauer DC, Drake MT. Osteoporosis management in the era of COVID-19. J Bone Miner Res. 2020;35(6):1009–1013. doi:10.1002/jbmr.4049
  • Girgis CM, Clifton-Bligh RJ. Osteoporosis in the age of COVID-19. Osteoporos Int. 2020;31(7):1189–1191. doi:10.1007/s00198-020-05413-0
  • Deeks ED. Denosumab: a review in postmenopausal osteoporosis. Drugs Aging. 2018;35(2):163–173. doi:10.1007/s40266-018-0525-7
  • Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the Phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513–523. doi:10.1016/S2213-8587(17)30138-9
  • Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48(4):677–692. doi:10.1016/j.bone.2010.11.020
  • Lamy O, Stoll D, Aubry-Rozier B, Rodriguez EG. Stopping denosumab. Curr Osteoporos Rep. 2019;17(1):8–15. doi:10.1007/s11914-019-00502-4
  • Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 2017;5(11):898–907. doi:10.1016/S2213-8587(17)30188-2
  • Imaz I, Zegarra P, González-Enríquez J, Rubio B, Alcazar R, Amate JM. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int. 2010;21(11):1943–1951. doi:10.1007/s00198-009-1134-4
  • Soong YK, Tsai KS, Huang HY, et al. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan. Osteoporos Int. 2013;24(2):511–521. doi:10.1007/s00198-012-1984-z
  • Fardellone P, Lello S, Cano A, et al. Real-world adherence and persistence with bisphosphonate therapy in postmenopausal women: a systematic review. Clin Ther. 2019;41(8):1576–1588. doi:10.1016/j.clinthera.2019.05.001
  • Hadji P, Papaioannou N, Gielen E, et al. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int. 2015;26(10):2479–2489. doi:10.1007/s00198-015-3164-4

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.